Table 3.
Dose and infection-type dependent risk of infection in patients treated with erenumab vs. Placebo
| Erenumab dose | Statistics | Infection | ||||
|---|---|---|---|---|---|---|
| Any | Viral | Bacterial | COVID-19* | UTI | ||
| Any | p- value | 0.753 | 0.464 | 0.921 | 0.008 | 0.561 |
| RR | 1.04 | 1.04 | 1.03 | 2.07 | 0.77 | |
| Clinical | p-value | 0.397 | 0.447 | 0.615 | 0.008 | 0.720 |
| RR | 1.05 | 1.05 | 1.15 | 2.07 | 0.88 | |
| High | p-value | 0.140 | 0.300 | 0.597 | 0.005 | 0.827 |
| RR | 1.13 | 1.12 | 1.19 | 2.35 | 0.92 | |
COVID-19 - Coronavirus disease 2019; *Only one study assessed COVID-19 frequency, so the results regarding this infection represent risk reported